Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings, Inc. reports developments tied to its clinical-stage biotherapeutics platform for oral delivery of biologics and drugs. The company’s RaniPill® capsule technology is designed to deliver drug substances such as antibodies, proteins, peptides and oligonucleotides as an alternative to subcutaneous injection or intravenous infusion.
Recurring RANI news includes clinical and preclinical updates for RaniPill-based programs, including RT-114, a GLP-1/GLP-2 dual agonist program for obesity, and oral semaglutide work. Company updates also cover financial results, collaboration and license activity, private placement financing, manufacturing and supply-chain capabilities, pipeline prioritization, investor conference participation, and leadership or advisory appointments supporting platform and clinical strategy.
Rani Therapeutics (Nasdaq: RANI) appointed Dr. Sara Kenkare-Mitra as a Strategic Advisor on April 9, 2026, to guide platform and clinical strategy.
Dr. Kenkare-Mitra brings nearly three decades of biologics and small molecule drug development experience and will advise on therapeutic focus, candidate selection, regulatory alignment, and development prioritization for RaniPill programs.
Rani Therapeutics (Nasdaq: RANI) reported Q4 and full-year 2025 results and a corporate update on March 26, 2026. Highlights include a Collaboration and License Agreement with Chugai worth up to $1.085 billion, an oversubscribed $60.3 million private placement, preclinical bioequivalence data for oral RT-114 (111% relative bioavailability) and oral semaglutide, and initiation of a Phase 1 study of RT-114. Cash and marketable securities totaled $49.7 million, which Rani expects to fund operations into Q4 2027.
Rani Therapeutics (Nasdaq: RANI) named Jesper Høiland Head of Strategy effective March 25, 2026. He joins after advising Rani since 2023 and brings 30+ years of pharmaceutical leadership with experience in obesity and metabolic disease.
Høiland will prioritize internal programs, evaluate therapeutic opportunities, and support partnering and business development for the RaniPill® oral biologics platform.
Rani Therapeutics (Nasdaq: RANI) will report fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026 after market close. Management will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT.
Investors can access the live webcast and a replay via the company’s investor relations website at www.ranitherapeutics.com.
Rani Therapeutics (Nasdaq: RANI) promoted Alireza Javadi, Ph.D., to Chief Technical Officer effective Jan. 28, 2026.
In his expanded role, Javadi will continue to lead R&D, manufacturing, and automation and will assume responsibility for quality assurance. Management cites his prior device and life‑sciences operations experience and his tenure at Rani since 2022.
Rani Therapeutics (Nasdaq: RANI) initiated a Phase 1 clinical trial on Jan 8, 2026 to evaluate RT-114, an oral RaniPill® capsule delivering PG-102, a GLP-1/GLP-2 dual agonist developed by ProGen, for the treatment of obesity.
The single- and multiple-dose study will assess safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics including weight-loss signals versus subcutaneous injection. Preclinical RT-114 data showed oral delivery with bioavailability, PK, and weight-loss comparable to subcutaneous dosing. ProGen previously reported preclinical and early clinical glucose-lowering and weight-loss signals for PG-102 at EASD 2025.
Rani Therapeutics (Nasdaq: RANI) announced that its management team will participate in the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 8:45 am ET in Coral Gables, FL.
Presenters include CEO Talat Imran and CFO Svai Sanford in a fireside chat and 1x1 meetings. Investors can watch a live webcast via the company Investor Relations website and access a replay after the presentation.
Rani Therapeutics (Nasdaq: RANI) reported Q3 2025 results and a corporate update on Nov 6, 2025.
Key items: a Collaboration & License Agreement with Chugai potentially worth up to $1.085 billion; an oversubscribed $60.3 million private placement closed in October 2025; appointment of Abraham Bassan and Vasudev Bailey, Ph.D. to the board; presentation of preclinical data showing oral semaglutide via RaniPill® with comparable bioavailability to subcutaneous dosing; and a plan to initiate a Phase 1 trial of RT-114 by end of 2025. Financials: cash, cash equivalents and marketable securities were $4.1 million as of Sept 30, 2025 (vs. $27.6 million at Dec 31, 2024); Q3 R&D was $3.2 million, G&A $4.0 million, and net loss $7.9 million (vs. $12.7 million in Q3 2024). The company expects funds from the private placement and Chugai deal to support operations into 2028.
Rani Therapeutics (Nasdaq: RANI) will present preclinical data on oral semaglutide (RT-116) delivered via the RaniPill® capsule at ObesityWeek® 2025.
The abstract reports that oral semaglutide in dogs was bioequivalent to subcutaneous injections and produced similar weight loss. The poster (No. 647) will be presented by Kyle Horlen, DVM, VP of Nonclinical Development, on November 6, 2025, 2:30–3:30 pm ET at the Georgia World Congress Center, Exhibit Hall A1; the meeting is Nov 4–7, 2025 and includes virtual participation.
Rani Therapeutics (Nasdaq: RANI) announced on October 23, 2025 the appointments of Abraham “Abe” Bassan and Vasudev Bailey, Ph.D., to its Board of Directors and the departures of Andrew Farquharson and Maulik Nanavaty.
The company highlighted strategic value from its clinical-stage pipeline and a recent collaboration with Chugai. Rani also closed a previously announced private placement expected to raise approximately $60.3 million, led by Samsara BioCapital with participation from Anomaly, RA Capital, Invus, Special Situations Funds and executive chairman Mir Imran.